Core Viewpoint - The company, Huisheng Biological, has a diverse product structure focused on veterinary pharmaceuticals, particularly for pigs, while also covering other areas such as poultry, aquaculture, pets, and ruminants [2] Product Structure - The company’s core product line is centered around pig medications, but it also includes a variety of products for other animal categories [2] - In the poultry segment, the company has developed several traditional Chinese veterinary medicine formulations, including Banqing Granules, Qizhen Zengmian Granules, and Qingwen Jiedu Oral Liquid [2] Clinical Efficacy - The mentioned products have shown significant clinical efficacy; however, further research is needed to confirm their effectiveness against avian influenza virus [2]

Core Insights - The company has reported a significant increase in the sales revenue of its raw material pharmaceutical segment, which has risen by 15 percentage points compared to the same period last year [1] Group 1: Business Performance - The raw material pharmaceutical business now constitutes a larger share of the company's overall revenue due to the deepening of its integrated raw material and formulation strategy [1] - In the veterinary formulation segment, the company is not only consolidating its advantages in the pig medicine business but is also actively expanding into poultry, aquaculture, and ruminant sectors, resulting in substantial revenue growth across these product lines [1] - Revenue from pig medicines accounts for approximately 80% of the total revenue from targeted animal categories [1]

Group 1 - The core viewpoint of the article highlights the significant growth in the sales revenue of the raw material drug business segment, which has increased by 15 percentage points compared to the same period last year due to the company's integrated strategy of raw materials and formulations [1] - In the veterinary formulations sector, the company is not only consolidating its advantages in the pig medicine business but also actively expanding into poultry, aquaculture, and ruminant sectors, resulting in substantial revenue growth across these product lines [1] - Revenue from pig medicines accounts for approximately 80% of the total revenue from targeted animal categories, indicating a strong reliance on this segment [1]